Navigation Links
TransCelerate BioPharma Inc. Grows, Strengthens Novel Effort to Accelerate Drug Development
Date:4/15/2013

PHILADELPHIA, April 15, 2013 /PRNewswire/ -- TransCelerate BioPharma Inc. ("TransCelerate") today announced that six new pharmaceutical companies have joined as members of the independent non-profit entity formed to assess, refine and create processes to bring innovative new medicines to the public faster. The addition of the new members to TransCelerate marks a major milestone since the organization's founding by ten healthcare and pharmaceutical companies in September 2012. The new member companies include Astellas Pharma Inc., the first member of TransCelerate headquartered in Japan, Biogen Idec, Braeburn Pharmaceuticals, EMD Serono, Inc. (a subsidiary of Merck KGaA, Darmstadt, Germany), Forest Research Institute (a subsidiary of Forest Laboratories, Inc.) and Onyx Pharmaceuticals.

By joining TransCelerate, each of the new companies will contribute financial and other resources, including personnel, to solve industry-wide challenges in a collaborative environment. With these six new members, combined with the ten original founding members, total membership in TransCelerate now stands at 16 companies.

"We are thrilled to expand the membership of TransCelerate BioPharma with these six new companies, we welcome them as members and we look forward to working with them," said Dalvir Gill , PhD, Chief Executive Officer of TransCelerate. "With the addition of these new members, TransCelerate extends its ability to impact global R&D and advance healthcare solutions worldwide."

As initial areas of focus, TransCelerate seeks to provide the following solutions: development of risk-based site monitoring approach and standards, development of a shared user interface for investigator site portals, mutual recognition of study site qualification and training, development of clinical data standards, and establishment of a comparator drug supply model.

"Together, we are leading the effort to develop shared industry solutions to simplify and accelerate the delivery of innovative products to patients – enabled by broad participation and collaboration across the global research and development community," said Dr. Gill.

About TransCelerate BioPharma Inc.

TransCelerate BioPharma Inc. was formed in 2012 and is a non-profit organization focused on advancing innovation in research and development (R&D), identifying and solving common R&D challenges and further improving patient safety, with the goal of delivering more high quality medicines to patients. TransCelerate evolved from discussions at various forums for executive R&D leadership to discuss relevant issues facing the industry and solutions for addressing common challenges. Founding members include Abbott/AbbVie, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, Johnson & Johnson, Pfizer, Genentech a member of the Roche Group, and Sanofi. Dalvir Gill , PhD, was named CEO in December of 2012.

Membership in TransCelerate is open to all pharmaceutical and biotechnology companies who can contribute to and benefit from these shared solutions. Executive offices are located in Philadelphia, PA. For more information, please visit http://www.transceleratebiopharmainc.com/.

Media Contacts:

Seema Kumar

(908) 218-6460

skumar10@its.jnj.com

Shannon Caudill

(740) 281-3715 or (614) 378-9042

shannon.caudill@porternovelli.com


'/>"/>
SOURCE TransCelerate BioPharma Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Biopharmaceutical Companies Transform Clinical Trial Strategies for Success in Global Marketplace
2. Americas Biopharmaceutical Companies Commitment to Research Remains Strong Despite Challenges
3. Absorption Systems Partners with Synerzys to Promote Biopharmaceutics Classification System (BCS) Testing of Drugs
4. In Q1 Public Biopharmas Shift Fundraising into Overdrive
5. Array BioPharma Announces Updates on ARRY-520 Clinical Data at the 2013 International Myeloma Workshop
6. Array BioPharma Names Michael N. Needle, M.D. As Chief Medical Officer
7. First Patients Dosed in Proof-of-Concept Clinical Study of Alder Biopharmaceuticals Lead Therapeutic Candidate for Treatment of Migraine, ALD403
8. Plato BioPharma Presenting Preclinical capabilities at PKPD Summit Boston
9. Keryx Biopharmaceuticals Announces Appointment of Amit Sharma, M.D. as Vice President, Medical Affairs
10. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2012 Financial Results
11. Keryx Biopharmaceuticals, Inc. To Host Conference Call on Fourth Quarter and Year-End 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)...  Patients in Alabama seeking prostate ... no longer have to travel out of state. Vituro ... Urology Centers of Alabama to provide a total prostate ... patients. Alabama is known ... prostate cancer using many different modalities. They are the largest ...
(Date:2/5/2016)... , Feb. 5, 2016 Aethlon Medical, Inc. ... , Chairman and CEO, will be presenting at Source Capital ... New York, NY at 2:15 p.m. ET on ... an Immunotherapy Panel discussion taking place at 3:15 p.m. ET. ... replay approximately one hour after the conclusion of the live ...
(Date:2/5/2016)... 5, 2016 Dehaier Medical Systems Ltd. ... "Company"), which develops, markets and sells medical devices ... China and international markets, today announced ... to concentrate the Company,s resources to develop its ... and to focus more on its major businesses. ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... February 05, 2016 , ... Love is in the air at ... of colors, assortments and packaging. This staple for Valentine’s Day is a must-have, and ... , For Valentine’s Day, not only are long-stem roses available, but also other flower ...
(Date:2/5/2016)... ... February 05, 2016 , ... The Muscular Dystrophy Association and ... launched the 14th annual “Appetite for a Cure” campaign on Feb. 1 to ... and related diseases that severely limit strength and mobility. , Now through ...
(Date:2/5/2016)... ... February 05, 2016 , ... The ... funding innovative lymphoma research and serving the lymphoma community through a comprehensive series ... again host, Swirl, A Wine Tasting Event at the La Gorce Country Club ...
(Date:2/5/2016)... Dallas, Texas (PRWEB) , ... February 05, 2016 , ... ... to allow users to search for and donate to Give To Cure’s campaign ... is an app that lets users make and share payments through a smart device. ...
(Date:2/5/2016)... MA (PRWEB) , ... February 05, 2016 , ... ... in tattoo technology, the PicoSure. Designed to provide the most effective tattoo removal today, ... option with unmatched results. , Developed by Cynosure, the PicoSure has been approved by ...
Breaking Medicine News(10 mins):